Albireo's elobixibat meets in Japanese Phase III study

Albireo AB (Gothenburg, Sweden) said elobixibat (AJG533/ A3309) met the primary endpoint in a Japanese Phase III study to treat chronic constipation. Compared with placebo, elobixibat significantly improved the number of weekly spontaneous bowel movements from baseline to the first treatment week.

EA Pharma Co. Ltd. (Tokyo, Japan) has exclusive rights in Japan and other Asian countries to elobixibat for gastrointestinal disorders. Albireo said that in 1Q17, EA plans to submit an NDA for elobixibat in Japan, which would trigger a milestone payment to Albireo. ...